PeptidesInfo
Benefits

Peptides for Muscle Growth: What the Evidence Supports

Growth-hormone peptides are sold almost entirely on muscle claims. No controlled trial has measured muscle with them. The one peptide with positive lean-mass data is the one nobody markets for it.

Abstract helix illustration for the muscle growth evidence analysis
Contents
  1. The short answer
  2. What the growth-hormone peptides actually demonstrate
  3. The test that has been run
  4. The surprising positive result
  5. The muscle question inside the GLP-1 story
  6. Muscle claims, graded
  7. What would change this
  8. Where to go next

Key findings

  1. 1No randomised controlled trial has measured muscle mass, cross-sectional area or strength with CJC-1295 or ipamorelin, alone or combined.
  2. 2Those peptides do reliably raise growth hormone and IGF-1 in short human studies — a hormone measurement, which is not the same as a muscle outcome.
  3. 3The closest benchmark is discouraging — growth hormone itself, given to healthy older adults across 31 studies, increased lean mass slightly but produced no improvement in strength or function.
  4. 4The one positive human lean-mass result belongs to collagen peptides combined with resistance training in older sarcopenic men, a finding that is surprising and under-replicated.
  5. 5Resistance training and adequate protein remain the interventions with overwhelming randomised evidence for muscle; no peptide has been shown to add to them.

Evidence level

Preclinical evidence

No controlled human trial has measured muscle mass or strength with CJC-1295 or ipamorelin. The strongest lean-mass finding in the peptide literature comes from collagen peptides combined with resistance training in older adults, on limited replication.

Regulatory status

Not FDA-approved

CJC-1295 and ipamorelin are not FDA-approved for any use and both development programmes were discontinued. Collagen peptides are a food ingredient with GRAS status.

Muscle is the reason most people search for growth-hormone peptides, and it is the outcome those peptides have never been tested against. The gap between what they demonstrably do — raise a hormone — and what they are sold to do is the widest in the peptide field.

The short answer

  • CJC-1295 and ipamorelin: no controlled trial has measured muscle mass, cross-sectional area or strength. Not once.
  • Growth hormone itself, the thing they raise, has been tested in older adults: lean mass rose slightly, strength and function did not improve.
  • Collagen peptides plus resistance training: the only positive human lean-mass result in the peptide literature, from one small trial.
  • Resistance training and protein: still the only interventions with overwhelming evidence.

What the growth-hormone peptides actually demonstrate

CJC-1295 has a genuine randomised placebo-controlled human study. In 53 healthy adults, single and repeated doses raised mean growth hormone two- to ten-fold for at least six days, and IGF-1 one-and-a-half to three-fold for nine to eleven days[1].

Study details: Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Study type
Randomised, placebo-controlled, phase 1
Population
Healthy adults aged 21–61
Sample size
53
Primary result
Single and repeated doses raised mean GH 2–10× for at least 6 days and IGF-1 1.5–3× for 9–11 days.
Limitations
Hormone endpoints only; no body-composition or strength measures.
Year
2006
Source
Journal of Clinical Endocrinology & Metabolism(link not yet independently re-verified)

That is a clean, replicated pharmacological finding. Read the endpoints column again though: hormone concentrations. No lean mass. No cross-sectional area. No one-rep max. No grip strength.

Ipamorelin is similar — designed to release growth hormone selectively without much cortisol or prolactin[4], tested in early human pharmacology, and never taken into a trial with a body-composition endpoint[5]. Its one outcome trial was in post-operative ileus, and it was negative.

The test that has been run

If the pitch is "more growth hormone means more muscle," the direct way to check is to give people growth hormone and measure muscle. That study exists — a systematic review of 31 studies in healthy older adults.

Lean body mass increased by roughly 2.1 kg. Fat mass fell by roughly 2.1 kg. And strength did not significantly improve. Neither did functional capacity[2].

Study details: Systematic review: the safety and efficacy of growth hormone in the healthy elderly
Study type
Systematic review of 31 studies
Population
Healthy older adults
Sample size
220
Primary result
Growth hormone increased lean body mass by about 2.1 kg and decreased fat mass by about 2.1 kg, with no significant improvement in strength or functional capacity.
Limitations
Studies were small and short; adverse effects were significantly more common.
Year
2007
Source
Annals of Internal Medicine(link not yet independently re-verified)

This is the single most important study in this article. A body-composition change on a scan that does not translate into being stronger or more capable is not the benefit people are buying. And this was growth hormone administered directly — the peptides are a less direct way of raising the same hormone.

The surprising positive result

The one peptide with a positive human lean-mass finding is the one nobody markets for muscle.

A 12-week randomised, double-blind, placebo-controlled trial in 53 sarcopenic men with a mean age around 72 found greater fat-free mass gains and greater strength increases when 15 g of collagen peptides was added to resistance training, compared with training plus placebo[3].

Study details: Collagen peptide supplementation in combination with resistance training improves body composition and increases muscle strength in elderly sarcopenic men
Study type
Randomised, double-blind, placebo-controlled
Population
Sarcopenic men, mean age approximately 72
Sample size
53
Primary result
Greater fat-free mass gain and greater strength increase with collagen peptides plus resistance training than with training plus placebo over 12 weeks.
Limitations
Small; single site; industry-funded; mechanism unclear given collagen's amino-acid profile.
Year
2015
Source
British Journal of Nutrition(link not yet independently re-verified)

Two honest notes. First, this result is mechanistically odd: collagen is a poor source of the essential amino acids that drive muscle protein synthesis, being low in leucine and lacking tryptophan. Either something other than amino-acid supply is at work, or the effect is smaller than it appears. Second, independent replication is limited and the trial was industry-funded. It stays preliminary — but it is the best human evidence on this page, and note that the training was doing the heavy lifting in both arms.

The muscle question inside the GLP-1 story

Worth flagging because it is the live research question in body composition right now: DEXA substudies from the large weight-loss trials show a meaningful fraction of the weight lost is lean tissue[6]. That is true of substantial weight loss by any method, but the scale here has made it a priority — which is why resistance training, protein intake and muscle-preserving co-therapies are being actively trialled alongside these drugs.

If your goal is body composition rather than weight, that distinction matters more than any secretagogue.

Muscle claims, graded

ClaimPeptideBest human evidenceGrade
Lean mass with resistance trainingCollagen peptides12-week RCT (n=53), older menPreliminary evidenceSmall, under-replicated
Raises GH and IGF-1CJC-1295Randomised study (n=53)Preliminary evidenceMechanism, cleanly shown
Increases muscle massCJC-1295, ipamorelinNonePreclinical evidenceNever measured
Increases strengthCJC-1295, ipamorelinNone; GH benchmark negativePreclinical evidenceNever measured
Improves recovery between sessionsCJC-1295, ipamorelinNonePreclinical evidenceNever measured
Muscle gains from the CJC/ipa stackCombinationNone for the combinationUnsupported evidenceUntested as a stack

What would change this

A randomised controlled trial with DEXA or MRI body composition and a strength endpoint, in trained or untrained adults, over at least twelve weeks. It is not an exotic study design — it is the standard one in exercise science, and it has simply never been run on these compounds.

We monitor ClinicalTrials.gov for registered trials with body-composition endpoints and will update the CJC-1295 and ipamorelin profiles when one appears.

Where to go next

Frequently asked questions

Do CJC-1295 and ipamorelin build muscle?
No controlled trial has measured it. They raise growth hormone and IGF-1 in short studies, which is a hormone result, not a muscle result.
If they raise growth hormone, shouldn't muscle follow?
That is the assumption being sold. It has been tested with growth hormone itself in older adults, where lean mass rose slightly but strength and function did not improve. Mechanism did not deliver the outcome.
Which peptide has the best muscle evidence?
Collagen peptides, oddly — a 12-week randomised trial in older sarcopenic men found greater fat-free mass and strength gains when combined with resistance training. It is one small trial with limited replication.
Do GLP-1 drugs cause muscle loss?
DEXA substudies show a portion of the weight lost is lean tissue, as with substantial weight loss by any means. This is why resistance training and adequate protein are studied alongside them.
What actually builds muscle?
Progressive resistance training with adequate protein, which has an overwhelming randomised evidence base. No peptide has been shown to add to it.

References

Numbered in order of first use. Study type is shown for every source; see our methodology for how we rank evidence.

  1. 1.

    Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism, 2006.

    Randomized controlled trialHealthy adults aged 21–61n = 53

    Result: Single and repeated doses raised mean GH 2–10× for at least 6 days and IGF-1 1.5–3× for 9–11 days.

    Limitations: Hormone endpoints only; no body-composition or strength measures.

    ↑ back to text
  2. 2.

    Liu H, Bravata DM, Olkin I, et al.. Systematic review: the safety and efficacy of growth hormone in the healthy elderly Annals of Internal Medicine, 2007.

    Systematic reviewHealthy older adultsn = 220

    Result: Growth hormone increased lean body mass by about 2.1 kg and decreased fat mass by about 2.1 kg, with no significant improvement in strength or functional capacity.

    Limitations: Studies were small and short; adverse effects were significantly more common.

    ↑ back to text
  3. 3.

    Zdzieblik D, Oesser S, Baumstark MW, Gollhofer A, König D. Collagen peptide supplementation in combination with resistance training improves body composition and increases muscle strength in elderly sarcopenic men British Journal of Nutrition, 2015.

    Randomized controlled trialSarcopenic men, mean age approximately 72n = 53

    Result: Greater fat-free mass gain and greater strength increase with collagen peptides plus resistance training than with training plus placebo over 12 weeks.

    Limitations: Small; single site; industry-funded; mechanism unclear given collagen's amino-acid profile.

    ↑ back to text
  4. 4.

    Raun K, Hansen BS, Johansen NL, et al.. Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology, 1998.

    Preclinical

    Result: Released growth hormone selectively without significant ACTH or cortisol release in animal models.

    Limitations: Preclinical characterisation; no human muscle outcomes.

    ↑ back to text
  5. 5.

    Clinical trials of ipamorelin (search) ClinicalTrials.gov.

    Trial registry

    Result: Registered phase 1/2 studies including post-operative ileus; no registered trials with body-composition or strength endpoints.

    ↑ back to text
  6. 6.

    Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) New England Journal of Medicine, 2022.

    Randomized controlled trialAdults with obesity without diabetesn = 2539

    Result: Mean weight change up to −20.9% at 72 weeks; DEXA substudies show a portion of loss is lean tissue.

    ↑ back to text

Review status: Editorially reviewed against primary sources. This article was fact-checked against the primary sources listed in the references by our editorial team, and it has not been reviewed by a licensed clinician. It is educational content, not medical advice. Read our editorial policy and methodology. Spotted an error? Tell us.

muscle growthlean massCJC-1295ipamorelincollagen peptidesgrowth hormonebenefits

Continue researching

Related analyses, profiles, and research areas

Recommendations are ranked by shared peptides, research areas, evidence level, and topic tags — not by popularity.

Benefits8 min read

Peptide Benefits: What the Evidence Actually Supports

Peptides are credited with dozens of benefits. Some are proven in large trials, some are modest and real, and some have never been tested in a person. This is every major benefit claim, sorted by how strong the human evidence is.

Benefits4 min read

Are Peptides Worth It? A Framework for Deciding

Whether a peptide is worth it depends on four things: what benefit is proven, in whom, for how long, and whether the effect lasts after you stop. Here is that framework applied to every peptide we cover.

Benefits4 min read

Peptides for Energy and Sleep: Claims Versus Trials

Better sleep and more energy are standard peptide selling points. No growth-hormone secretagogue has been tested with sleep laboratory measurement, and the one peptide with a large sleep trial works by a completely different route.